<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01745133</url>
  </required_header>
  <id_info>
    <org_study_id>OLX0112</org_study_id>
    <nct_id>NCT01745133</nct_id>
  </id_info>
  <brief_title>Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis</brief_title>
  <official_title>Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leon Kircik, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stiefel, a GSK Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Derm Research, PLLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate if combined use of OLUX-E™ Foam and SORILUX Foam
      may help &quot;maintain&quot; the therapeutic benefit that is achieved with OLUX-E™ Foam in the
      treatment of moderate plaque psoriasis.

      OLUX-E™ is a medication that contains a corticosteroid delivered in a foam formulation.
      SORILUX Foam is a foam formulation of calcipotriene. Both medications have been approved by
      the FDA for treating plaque psoriasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, investigator-blind study. Approximately 60 qualified subjects will
      be enrolled into a 2 week treatment phase where they will receive 2 weeks of treatment with
      Olux E foam. After 2 weeks treatment, subjects with a PGA of 0 or 1 will be re-randomized
      into maintenance phase.

      Subjects that achieve PGA scores of &gt;2 will be discontinued from the study and will not be
      randomized. Subjects that achieve PGA scores of 0 or 1 will enter an 8 week maintenance phase
      where they will be randomized on a 1:1:1 basis to one of the following treatment groups:

        -  Vehicle foam (BID)

        -  Sorilux foam (BID)

        -  Sorilux foam (BID on weekdays) + Olux E foam (BID on weekends)

      Subjects will then attend clinic visits at week 6. At week 10 study treatment will be
      stopped.

      The maximum duration of the study is 10 weeks and consists of a Screening/Baseline Visit
      (Week -0), Re-randomization to maintenance phase visit (Week 2), treatment follow-up visits
      at Weeks 6, and end of treatment visit at weeks 10.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Physician Global Assessement</measure>
    <time_frame>10 weeks</time_frame>
    <description>Percentage of participants with clear or almost clear skin on the PGA scale. 0 = clear
= almost clear
= mild
= moderate
= severe</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>clobetasol propionate 0.05% twice a day for two weeks; then vehicle foam twice a day every day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>calcipotriene</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day every day for 8 weeks x</description>
  </arm_group>
  <arm_group>
    <arm_group_label>calcipotriene + clobetasol propionate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day on weekdays for 8 weeks + clobetasol propionate 0.05% foam twice a day on weekends for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vehicle foam</intervention_name>
    <description>clobetasol propionate 0.05% twice a day for two weeks; then vehicle foam twice a day every day for 8 weeks</description>
    <arm_group_label>vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>calcipotriene</intervention_name>
    <description>clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day every day for 8 weeks</description>
    <arm_group_label>calcipotriene</arm_group_label>
    <other_name>Sorilux foam 0.005% foam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>calcipotriene + clobetasol propionate</intervention_name>
    <description>clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day on weekdays + clobetasol propionate 0.05% foam twice a day on weekends for 8 weeks</description>
    <arm_group_label>calcipotriene + clobetasol propionate</arm_group_label>
    <other_name>Sorilux foam + Olux E foam</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatient, male or female subjects of any race, 18 years of age or higher. -Female
             subjects of childbearing potential must have a negative urine pregnancy test within 7
             days prior to the first dose of study drug and practice a reliable method of
             contraception throughout the study [Exception: Female subjects of child bearing
             potential who are not sexually active are not required to practice a reliable method
             of contraception and may be enrolled at the Investigator's discretion provided they
             are counseled to remain sexually inactive for the duration of the study and understand
             the risks involved in getting pregnant during the study.]

          -  Moderate plaque type psoriasis eligible for topical therapies.

          -  A Bod Surface Area (BSA) of 3-10%.

          -  Physician Global Assessment(PGA) score of 3.

          -  Able to understand study requirements and sign Informed Consent/Health Insurance
             Portability and Accountability Act forms.

        Exclusion Criteria:

          -  Female subjects who are pregnant, breast-feeding, or who are of childbearing potential
             and not practicing a reliable method of birth control, or male subjects planning a
             pregnancy with their spouse or partner while in the study.

          -  History of hypocalcaemia or vitamin D toxicity.

          -  Serious skin condition (other than psoriasis) or uncontrolled medical condition (in
             the opinion of the investigator).

          -  Topical steroids, topical immunomodulators, topical vitamin D derivatives, tar,
             salicylic acid, anthralin or any other topical treatment for psoriasis within 2 weeks
             of baseline.

          -  Use of any biologics within 3 months of baseline.

          -  Use of other systemic psoriasis treatments (ie, oral retinoids, methotrexate,
             cyclosporine, or other immunomodulators) within 4 weeks of baseline.

          -  Use of Ultraviolet B light (UVB) or oral psoralen with ultraviolet A (PUVA) within 2
             weeks of baseline.

          -  Skin conditions (e.g. eczema) psoriasis that may interfere with evaluations of
             psoriasis.

          -  Known hypersensitivity to Sorilux Foam Ointment or any of its components.

          -  Known hypersensitivity to Olux E Foam or any of its components.

          -  Contraindications according to the Sorilux Foam or Olux E Foam package inserts.

          -  Current drug or alcohol abuse (Investigator opinion).

          -  Subject unable to commit to all the assessments required by the protocol.

          -  Current enrollment in another clinical study and treatment with another experimental
             drug or approved therapy for experimental use within 30 days prior to the Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leon H Kircik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>DermResearch, PLLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DermResearch, PLLC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2012</study_first_submitted>
  <study_first_submitted_qc>December 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2012</study_first_posted>
  <results_first_submitted>August 18, 2016</results_first_submitted>
  <results_first_submitted_qc>November 15, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 17, 2016</results_first_posted>
  <last_update_submitted>November 15, 2016</last_update_submitted>
  <last_update_submitted_qc>November 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Derm Research, PLLC</investigator_affiliation>
    <investigator_full_name>Leon Kircik, M.D.</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>Olux E foam</keyword>
  <keyword>Sorilux foam</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clobetasol</mesh_term>
    <mesh_term>Calcipotriene</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>5 screen failure</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vehicle 19</title>
          <description>clobetasol propionate 0.05% twice a day for two weeks; then vehicle foam twice a day every day for 8 weeks
vehicle foam: clobetasol propionate 0.05% twice a day for two weeks; then vehicle foam twice a day every day for 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>Calcipotriene 20</title>
          <description>clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day every day for 8 weeks x
calcipotriene: clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day every day for 8 weeks</description>
        </group>
        <group group_id="P3">
          <title>Calcipotriene + Clobetasol Propionate 20</title>
          <description>clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day on weekdays for 8 weeks + clobetasol propionate 0.05% foam twice a day on weekends for 8 weeks
calcipotriene + clobetasol propionate: clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day on weekdays + clobetasol propionate 0.05% foam twice a day on weekends for 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vehicle 19</title>
          <description>clobetasol propionate 0.05% twice a day for two weeks; then vehicle foam twice a day every day for 8 weeks
vehicle foam: clobetasol propionate 0.05% twice a day for two weeks; then vehicle foam twice a day every day for 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>Calcipotriene 20</title>
          <description>clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day every day for 8 weeks x
calcipotriene: clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day every day for 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>Calcipotriene + Clobetasol Propionate 20</title>
          <description>clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day on weekdays for 8 weeks + clobetasol propionate 0.05% foam twice a day on weekends for 8 weeks
calcipotriene + clobetasol propionate: clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day on weekdays + clobetasol propionate 0.05% foam twice a day on weekends for 8 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="19"/>
            <count group_id="B4" value="58"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="07"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Physician Global Assessement</title>
        <description>Percentage of participants with clear or almost clear skin on the PGA scale. 0 = clear
= almost clear
= mild
= moderate
= severe</description>
        <time_frame>10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vehicle 68%</title>
            <description>clobetasol propionate 0.05% twice a day for two weeks; then vehicle foam twice a day every day for 8 weeks
vehicle foam: clobetasol propionate 0.05% twice a day for two weeks; then vehicle foam twice a day every day for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Calcipotriene 80%</title>
            <description>clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day every day for 8 weeks x
calcipotriene: clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day every day for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Calcipotriene + Clobetasol Propionate 79%</title>
            <description>clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day on weekdays for 8 weeks + clobetasol propionate 0.05% foam twice a day on weekends for 8 weeks
calcipotriene + clobetasol propionate: clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day on weekdays + clobetasol propionate 0.05% foam twice a day on weekends for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Physician Global Assessement</title>
          <description>Percentage of participants with clear or almost clear skin on the PGA scale. 0 = clear
= almost clear
= mild
= moderate
= severe</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Vehicle</title>
          <description>clobetasol propionate 0.05% twice a day for two weeks; then vehicle foam twice a day every day for 8 weeks
vehicle foam: clobetasol propionate 0.05% twice a day for two weeks; then vehicle foam twice a day every day for 8 weeks</description>
        </group>
        <group group_id="E2">
          <title>Calcipotriene 80%</title>
          <description>clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day every day for 8 weeks x
calcipotriene: clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day every day for 8 weeks</description>
        </group>
        <group group_id="E3">
          <title>Calcipotriene + Clobetasol Propionate 79%</title>
          <description>clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day on weekdays for 8 weeks + clobetasol propionate 0.05% foam twice a day on weekends for 8 weeks
calcipotriene + clobetasol propionate: clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day on weekdays + clobetasol propionate 0.05% foam twice a day on weekends for 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>right hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>worsening of burning and itching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>small population</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>leon kircik</name_or_title>
      <organization>DermResearch PLLC</organization>
      <phone>5023965310</phone>
      <email>wedoderm@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

